Latest Conference Articles

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access.

Experts at AMCP 2026 urged smarter oncology management amid rising costs, complex therapies, and fragmented oversight across plans.

During an afternoon AMCP 2026 session, experts called for integrated clinical and payer care models to combat rising metabolic disease prevalence, costs, and complexity.

At AMCP 2026, Daryl Pritchard, PhD, highlighted fragmentation, evidence gaps, and decision support needs limiting precision medicine adoption and outcomes.

Kelsea Aragon, PharmD, highlights the role of long-acting HIV therapies like lenacapavir and cabotegravir in improving adherence, flexibility, and prevention access.

An AMCP 2026 session emphasized the need to shift to workflow-integrated AI by 2030 and stressed the importance of governance, trust, and scalable implementation.

Patty Taddei-Allen, PharmD, MBA, warns that co-pay accumulators and maximizers may lower plan costs but increase patient burden and disrupt medication adherence.

Adam Colburn, JD, highlights 3 federal bills to expand value-based care, digital therapeutics, and pharmacist reimbursement across Medicare and Medicaid.

Experts at AMCP 2026 outlined volatility across the health care landscape that may impact the upcoming midterm elections.

Two posters presented at AMCP 2026 found low dry eye disease (DED) treatment uptake and frequent discontinuation among Medicare patients, whereas comorbid DED did not affect glaucoma adherence.

Two posters presented at AMCP 2026 suggest improving GLP-1 adherence and access may enhance outcomes and lower obesity-related costs.

Psychological effects of alopecia areata should be looked into in the future for patients who live with the condition.

Health care professionals will gather in Nashville next week for AMCP 2026 to discuss key topics in the space, including AI use and medication access.

Two AAD 2026 posters highlight persistent melanoma disparities: men have worse survival, whereas minority patients are less likely to receive home or hospice end-of-life care.

Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.

Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.

Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.

Continuing conversations from last year, experts at the AAD Annual Meeting in Denver weighed the pros and cons of teledermatology and AI.

Key session speakers and abstract presenters share their highlights of attending AAD 2026.

A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.

Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients with indolent systemic mastocytosis.

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib.

Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers.

This morning, experts delivered "short and sweet" updates on treatment strategies for common dermatologic conditions.

Experts at the 2026 AAD Annual Meeting urged dermatologists to engage in advocacy to protect practices and patient access amid growing challenges.

Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa.

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD.

Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy.